Effects of nanocurcumin in the treatment of non-alcoholic fatty liver disease

The clinical trial of effects of nanocurcumin supplementation on blood nesfatin, insulin resistance indexes, lipids and inflammatory factors in overweight and obese patients with non-alcoholic fatty liver disease ??(NAFLD)?

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016071915536N3

Enrollment

Registered

2016-08-02

Start date

2016-08-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non alcoholic fatty liver disease. Nonalcoholic steatohepatitis, Nonalcoholic fatty liver disease

Interventions

Intervention 1: Intervention Group: Nanocurcumin supplementation with dose of 80mg (40mg bid with breakfast and dinner meals) for 3 months. Intervention 2: Placebo Group: Placebo supplementation with

Treatment - Other

Placebo

Intervention Group: Nanocurcumin supplementation with dose of 80mg (40mg bid with breakfast and dinner meals) for 3 months.

Placebo Group: Placebo supplementation with dose of 80mg (40mg bid with breakfast and dinner meals) for 3 months.

Eligibility

Sex/Gender

All

Age

25 Years to 50 Years

Inclusion criteria

Inclusion criteria: Inclusion Criteria:? Non-alcohilic fatty liver disease diagnosed by a radiologist and hepatologist using ?ultrasonography into one of three categories (mild, moderate or severe degree); Age 25–50 years; Overwight or obesity (25=BMI90/140 mmHg)?; Any diagnosed malignancy; Breast-feeding, pregnancy and or plan for pregnancy in the next 3 months; Professional athlete or regular exercise; Treatment with statins, antihypertensive and ursodeoxy colic acid, probiotics and ?multivitamin-mineral and antioxidant supplements during the three months prior to the ?intervention; Surgery for weight loss in the last year and weight loss program for the past three month; Taking a multivitamin-mineral and or antioxidants supplement at least once a week during the ?study; Not taking more than 10% of prescription supplements?

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Nesfatin. Timepoint: At the beginning and end of intervention. Method of measurement: serum levels (ng/ml?) by Elisa.	—

Secondary

Measure	Time frame
ALT/AST/TG/TC/HDL/LDL/FBS/FBI/HbA1C/TNF-Alpha/IL-6/hs-CRP. Timepoint: At the beginning and end of intervention. Method of measurement: Serum levels by Elisa.;Blood pressure, Body composition, Body Mass Iindex, Waist Circumference. Timepoint: At the beginning and end of intervention. Method of measurement: Mercury manometer, BIA, Formula, Tape measure (mmhg, %, kg/m2, cm), respectively.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad-Javad Hosseinzadeh-Attar

School of Nutritional Sciences and Dietetics, Tehran University of Medical Sciences?

mhosseinzadeh@tums.ac.ir+98 21 8895 5569

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Mar 4, 2026